EUVIMEDEUVIMED entdecken
Crossref

Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death

Xinyun Zhang, Zhiming Wang, Yilei Shi, Qi Li, Si Chen, Lexin He, Yali Chai, Hao Xu, Yuchen Zhang, Meifang Zhao, Wenzhuo Zhuang, Bingzong Li

Apoptosis · 2026

DOI: 10.1007/s10495-026-02426-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apoptosis, 2026. Verfasst von Xinyun Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, the Second Affiliated Hospital of Soochow University, San Xiang Road 1055, Suzhou, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Proteasome Inhibitors, Immunogenic Cell Death, Drug Resistance, Neoplasm. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to proteasome inhibitors (PIs) and inadequate engagement of anti-tumor immunity remain major barriers to effective treatment of multiple myeloma (MM). Here, we identified anwulignan, a bioactive natural product, as a translationally promising agent that retains activity in PI-resistant MM cells and promotes anti-myeloma immune responses. Anwulignan demonstrated potent cytotoxic activity against MM cells and exhibited strong synergy with proteasome inhibitors both in vitro and in vivo. In mouse MM models, anwulignan significantly suppressed tumor growth while maintaining favorable tolerability and safety profiles. Mechanistically, nucleophosmin 1 (NPM1) has been identified as a direct molecular target of anwulignan. Elevated NPM1 expression correlates with poor clinical outcomes in MM, and its inhibition by anwulignan induces cell cycle arrest and apoptosis. In addition to its tumor-intrinsic cytotoxic effects, anwulignan activated the caspase-1-dependent gasdermin D (GSDMD) pyroptosis pathway, thereby inducing immunogenic cell death. Genetic silencing of GSDMD markedly impaired anwulignan-mediated tumor suppression in vitro and in vivo, highlighting pyroptosis as a critical effector mechanism. In immunocompetent syngeneic MM models, anwulignan treatment increased bone marrow and splenic T-cell proportions and achieved superior tumor control compared with GSDMD-deficient tumors. Collectively, these findings establish anwulignan as a dual-function therapeutic that directly targets MM cell survival while simultaneously promoting anti-tumor immunity through pyroptosis-driven immunogenic cell death. This study provides a strong translational rationale for leveraging natural products as immune-engaging strategies to target drug-resistant multiple myeloma and improve therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaProteasome InhibitorsImmunogenic Cell DeathDrug Resistance, NeoplasmAnimalsHumansMiceCell Line, TumorNucleophosminApoptosisPyroptosis

Stichwörter der Autor:innen

AnwulignanImmunogenic cell deathMultiple myelomaProteasome inhibitorsPyroptosis

Substanzen

Proteasome InhibitorsNucleophosminNPM1 protein, humanNpm1 protein, mouse

Autor:innen und Institutionen

  • Department of Hematology, the Second Affiliated Hospital of Soochow University, San Xiang Road 1055, Suzhou, China.
  • Department of Pharmacy, the Second Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, 215123, Ren Ai Road 199, Suzhou, China.
  • Suzhou Sano Precision Medicine Ltd, Suzhou, China.
  • Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, 215123, Ren Ai Road 199, Suzhou, China. zhuangwenzhuo@suda.edu.cn.
  • Department of Hematology, the Second Affiliated Hospital of Soochow University, San Xiang Road 1055, Suzhou, China. lbzwz0907@hotmail.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Wang, Z., Shi, Y., Li, Q., Chen, S., He, L., Chai, Y., Xu, H., Zhang, Y., Zhao, M., Zhuang, W., & Li, B. (2026). Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death. Apoptosis. https://doi.org/10.1007/s10495-026-02426-8

Vancouver

Zhang X, Wang Z, Shi Y, Li Q, Chen S, He L, et al. Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death. Apoptosis. 2026. doi:10.1007/s10495-026-02426-8

BibTeX
@article{Zhang2026,
  author = {Zhang, Xinyun and Wang, Zhiming and Shi, Yilei and Li, Qi and Chen, Si and He, Lexin and Chai, Yali and Xu, Hao and Zhang, Yuchen and Zhao, Meifang and Zhuang, Wenzhuo and Li, Bingzong},
  title = {Activating a novel cell death pathway to target PI-resistant multiple myeloma and enhance immunogenic cell death},
  journal = {Apoptosis},
  year = {2026},
  doi = {10.1007/s10495-026-02426-8}
}
Kostenlos starten →